MinLibCas9 Citations (4)

Originally described in: Minimal genome-wide human CRISPR-Cas9 library.
Gonçalves E, Thomas M, Behan FM, Picco G, Pacini C, Allen F, Vinceti A, Sharma M, Jackson DA, Price S, Beaver CM, Dovey O, Parry-Smith D, Iorio F, Parts L, Yusa K, Garnett MJ Genome Biol. 2021 Jan 21;22(1):40. doi: 10.1186/s13059-021-02268-4. PubMed Journal

---

Articles Citing MinLibCas9

Articles
CRISPR activation screening in a mouse model for drivers of hepatocellular carcinoma growth and metastasis. Zhang B, Ren Z, Zheng H, Lin M, Chen G, Luo OJ, Zhu G. iScience. 2023 Feb 2;26(3):106099. doi: 10.1016/j.isci.2023.106099. eCollection 2023 Mar 17. PubMed
High-throughput screening of genetic and cellular drivers of syncytium formation induced by the spike protein of SARS-CoV-2. Chan CWF, Wang B, Nan L, Huang X, Mao T, Chu HY, Luo C, Chu H, Choi GCG, Shum HC, Wong ASL. Nat Biomed Eng. 2023 Nov 23. doi: 10.1038/s41551-023-01140-z. PubMed
CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy. Qin M, Deng C, Wen L, Luo G, Meng Y. J Transl Med. 2024 May 30;22(1):516. doi: 10.1186/s12967-024-05235-2. PubMed
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance. Watterson A, Picco G, Veninga V, Samarakoon Y, Cattaneo CM, Vieira SF, Karakoc E, Bhosle S, Battaglia TW, Consonni S, Halim TYF, Voest EE, Garnett MJ, Coelho MA. Cell Rep Med. 2026 Jan 20;7(1):102565. doi: 10.1016/j.xcrm.2025.102565. PubMed

If you have published an article using this material, please email us at to have your article added to this page.